HYPERREFLECTIVE FOCI PRECEDE MACULAR NEOVASCULARIZATION FORMATION IN ANGIOID STREAKS

Retin Cases Brief Rep. 2023 Jul 1;17(4):392-396. doi: 10.1097/ICB.0000000000001201.

Abstract

Purpose: To describe the steps leading to the development and progression of macular neovascularization (MNV) in angioid streaks.

Methods: The study was designed as retrospective, longitudinal case series. Patients with angioid streaks were investigated by means of multimodal imaging, including fundus autofluorescence and structural optical coherence tomography. Main outcome measures were hyperreflective foci and MNV progression steps.

Results: Overall, 40 eyes (20 patients) affected by angioid streaks were evaluated. Over the follow-up, five eyes of five patients developed MNV. The mean follow-up was of 1.6 years. The mean number of anti-vascular endothelial growth factor injections was 4.35 ± 1.4. Mean best-corrected visual acuity was 0.53 ± 0.38 LogMAR at the MNV onset, improving to 0.42 ± 0.40 LogMAR at the end of the follow-up ( P > 0.05). Intraretinal hyperreflective foci onset and coalescence represented the first alterations occurring before the onset of the MNV. Anti-vascular endothelial growth factor treatment was associated with exudation relapsing and remitting, with still present intraretinal hyperreflective foci and pigment accumulation. The longitudinal analysis of our cohort of eyes outlined the event timeline: 1.2 months to find concentrated hyperreflective foci, 4.5 months to observe pigment organization through the outer nuclear layer, and 1.5 years to detect MNV.

Conclusion: Hyperreflective foci formation, concentration, and migration represent early alterations occurring before the onset of the MNV in angioid streaks.

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Angioid Streaks* / complications
  • Angioid Streaks* / diagnosis
  • Angioid Streaks* / drug therapy
  • Choroidal Neovascularization* / complications
  • Choroidal Neovascularization* / diagnosis
  • Choroidal Neovascularization* / drug therapy
  • Endothelial Growth Factors / therapeutic use
  • Fluorescein Angiography
  • Follow-Up Studies
  • Humans
  • Intravitreal Injections
  • Retina
  • Retrospective Studies
  • Tomography, Optical Coherence / methods

Substances

  • Angiogenesis Inhibitors
  • Endothelial Growth Factors